This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS Kisqali for early breast cancer, Merck’s MRK Keytruda for malignant pleural...
This two-step strategy could set investors up with a large sum of passive income in retirement.
Shares of Intuitive Surgical ISRG have risen 14.2% in the past three months, outperforming the Zacks Medical - Instruments industry’s growth of 3.8% and the broader Zacks Medical sector’s return of...
Teva Pharmaceutical Industries Limited’s TEVA stock has risen 72.5% so far this year compared with an increase of 17.9% for the industry. The stock has also outperformed the sector and the S&P 500, as...
This week, the FDA approved J&J’s JNJ Tremfya for treating an inflammatory bowel disease condition (“IBD”), ulcerative colitis. Novo Nordisk’s NVO oral obesity pill, amycretin, showed faster weight...
The biotech continues to earn important wins, but is it enough?
Johnson & Johnson JNJ announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely...
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic.
You can take these dividends straight to the bank.
/Johnson%20%26%20Johnson%20location%20sign-by%20JHVEPhoto%20via%20iStock.jpg)
Johnson & Johnson has underperformed the S&P 500 recently, but analysts are moderately optimistic about the stock’s potential.